A Model for Prediction of Pelvic Inflammatory Disease and Acute Appendicitis in Childbearing-aged Women who Visit the Emergency Department with Abdominal Pain

Department of Emergency Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Department of Emergency Medicine, Gachon University Gill Hospital, Incheon, Korea¹ Joong Wan Park, M.D., Jong Hwan Shin, M.D., Kyoung Jun Song, M.D., Jin Joo Kim, M.D.¹

Purpose: We evaluated important factors for pelvic inflammatory disease (PID) and acute appendicitis, respectively, and we developed scoring systems for use in screening for PID or acute appendicitis in childbearing-aged women who

visit the emergency department (ED) with abdominal pain. **Methods**: By performance of multivariable logistic regression analysis, we found statistically significant factors for PID and acute appendicitis in prospectively collected registries, and we developed scoring systems for screening of each disease. The performances of these scoring systems were compared using the area under the receiver operating characteristics (ROC) curve.

Results: A total of 1048 patients were registered. Among them, 279 patients diagnosed as PID (155 patients) or acute appendicitis (124 patients) were finally analyzed in this study. The significant factors that favored PID were a length of pain onset more than two days, a history of coitus within four weeks, fever, a history of abortion, vaginal secretions, taking a painkiller for dysmenorrhea, diffuse low abdominal tenderness, no migration of pain, absence of gastrointestinal symptoms, and no leukocytosis. The significant factors that favored acute appendicitis were directly contrary to the significant factors for PID. Each of these variables was assigned a score of 1 or 2. The ROC areas of PID and acute appendicitis were 0.896 and 0.910, respectively.

Conclusion: In order to screen for PID and acute appendicitis, among other diseases, using eleven important factors, we developed scoring systems for childbearing-aged women who present with abdominal pain. Conduct of further prospective study that will utilize these scoring systems is needed.

책임저자: 신 종 환 서울특별시 동작구 보라매로5길 20 보라매병원 응급의학과 Tel: 02) 870-2662, Fax: 02) 831-2826 E-mail: skyshin1@dreamwiz.com 접수일: 2012년 8월 6일, 1차 교정일: 2012년 8월 20일 게재승인일: 2012년 10월 27일 Key Words: Pelvic inflammatory disease, Appendicitis, Abdominal pain

Introduction

Making the diagnosis of childbearing-aged women who are admitted to the emergency department (ED) with abdominal pain is more complicated than that of male patients. Furthermore, patients who have infectious diseases at the upper gynecological organs or more progressive gynecological infection at the intra-abdominal organs with a resolved infection at the low gynecological organs could be misdiagnosed as various diseases that have similar symptoms¹⁻⁴⁾. These kinds of misdiagnosis might lead inappropriate treatment for patients in the ED. Especially, a patient who has pelvic inflammatory disease (PID) or PID-related diseases might be discharged from the ED after only symptomatic treatment for abdominal pain without a confirmed diagnosis, antibiotic treatment and follow-up. To avoid situations like this, more sophisticated and unpleasant gynecological examinations for differentiating between different gynecological diseases, in conjunction with consulting a surgeon for making the differentiation of surgical abdominal diseases, are required. This complex process may prolong the stay of patients in the ED and result in overcrowding in the ED, and some patients have expressed dissatisfaction with this process. However, emergency physicians may not always make the accurate diagnosis of PID or acute appendicitis by using only the physical examination and routine ED laboratory results. Finally, patients may need expensive studies such as ultrasonography, abdominal-pelvis computed tomography (CT) and magnetic resonance imaging (MRI) for a precise diagnosis, and CT is hazard to childbearing-aged women due to the radiation exposure⁵⁻⁷⁾. Therefore, we

evaluated the clinical predictive factors that are easy to ask and examine when screening for PID and acute appendicitis in childbearing-aged women who present with abdominal pain, and then we developed a scoring system that is feasible to use in the ED.

Material and Methods

1. Design, registry and predictor variables

This study is a prospective cross-sectional analysis. We have collected the registries of childbearing-aged women who presented with abdominal pain at urban EDs from April 2008 to October 2010. This study was approved by the institution review board (IRB number 20100203/6-2010-77/92) at our hospital, which is metropolitan academic teaching hospital with 40,000 annual ED visitors. The enrolled subjects were childbearingaged women who presented to the ED with abdominal pain. But the patients who were pregnancy, those who had abdominal pain and presented with known diseases and those who were before the age of menarche or after menopause were excluded from our study. Patients were also excluded if they had undergone prior abdominal surgery such as appendectomy. The registries of the childbearing-aged women included information about age, the onset of pain, the marriage status, the obstetric history, a history of gynecologic infection (PID), a history of abortion, a history of other gynecologic diseases, the last menstrual period, the presence of vaginal secretions and dysmenorrhea, taking a painkiller for dysmenorrhea, a history of sexual contact, the use of an intrauterine device, fever (body temperature >37.8 degree centigrade), the location of pain, migration of pain, the location of abdominal tenderness, the presence of rebound tenderness, the gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea and postprandial pain), the urinary symptoms (dysuria, hematuria and frequency) and costovetebral angle tenderness (CVAT). This registry was recorded by emergency physicians at the first medical examination. The laboratory data, included the total leukocyte count, the C-reactive protein (CRP) level and the urinary sediment for pyuria, was examined by quantitative analyses. The final diagnosis was identified by performing chart review. PID was confirmed by gynecologist's examination according to the 2006 CDC guideline for PID and PID-related diseases. Tubo-ovarian abscess (TOA) and Fits-Hugh-Curtis syndrome (FHCS) were included in the PID-related diseases, which were diagnosed by using trans-vaginal sonography or CT. Acute appendicitis was diagnosed by abdominal ultrasonography or CT and this was followed by a surgeon performing appendectomy and it was finally confirmed by pathological examination.

2. Statistical analysis

Statistical analysis was performed using SPSS version 12.0 (SPSS Inc., Chicago, IL). Univariate analyses involved identified Two-independent samples test for the nominal variables and Student t test for the continuous variables. We identified the significant predictive variables for PID and acute appendicitis, respectively, by the use of multivariable logistic regression analyses, along with the 95% confidence interval (CI). All the items that were included in our registry and the laboratory findings were for assessing the predictive variables within the statistical analysis. Variables were removed from the predictor variables based on the chi-square p-value in the multivariable logistic regression model, beginning with the variables with the highest p-values. After multivariable logistic regression analysis, the adjusted prevalence odds ratios (ORs) and the associated 95% CIs of the statistically significant predictive variables that affect the diagnosis of PID and acute appendicitis, respectively, were obtained. We created applicable weighted clinical risk scores for PID and acute appendicitis, respectively, by using the β -coefficients corresponding to each predictor in the final analyses. Each distribution of β -coefficients between the maximum and minimum values was divided into 2 intervals, and we assigned a proper score to each of the predictive variables with a range of scores of 1 or 2. We then made the PID score and acute appendicitis score for the screening models, respectively. The performances of both scores were evaluated by using the receiver operating characteristics (ROC) areas. Two cutoff points for each of the ROC areas were selected by using the points according to the sensitivity or specificity over 95%, and the likelihood ratios were obtained for each of the cutoff points of the PID score and the acute appendicitis score, respectively. Finally the proportions

of the probability of PID and acute appendicitis were calculated and divided into the low, intermediate and high risk groups, respectively.

Results

1. Study population and characteristics

A total of 1048 eligible childbearing women patients were registered in our study. The registries of 14 patients did not have complete data for some variables and analyses were excluded from the statistical analysis. Table 1 shows the disease categories of the enrolled patients. There were 155(14.8%) patients who had PID and PID-related diseases and 124(11.8%) patients who had acute appendicitis. Finally 279 patients were analyzed in this study. The range of age was between 13 and 51, and the mean age of the enrolled patients was 28.9 ± 8.0 years old.

2. Multivariable logistic regression analyses

The clinical characteristics of the study population with PID and acute appendicitis are shown in Table 2. After the multivariable logistic regression analysis, the number of statistically significant predictive variables for PID and acute appendicitis was ten for each. The statistically significant predictive variables that favored PID were a length of pain onset more than 2 days, a coitus history within 4 weeks, fever, a history of abortion, vaginal secretions, taking a painkiller for dysmenorrhea, diffuse low abdominal tenderness, no migration of pain, the absence of GI symptoms and no leukocytosis (white

Table 1. The diseases categories of the registered patients

| Diseases categories | N (%)* |
|---|------------|
| $PID^{\dagger} & PID^{\dagger}$ -related diseases ($PID^{\dagger}, TOA^{\dagger}, FHCS^{\$}$) | 155 (14.8) |
| Other gynecologic diseases | 150 (14.3) |
| Gastrointestinal diseases | 344 (32.8) |
| Acute appendicitis | 124 (11.8) |
| Urologic diseases | 103 (9.8) |
| Unconfirmed diseases | 306 (29.2) |
| Total | 1064 |

* N: number

⁺ PID: pelvic inflammatory disease

[†] TOA: tubo-ovarian abscess

[§] FHCS: fitz-hugh-curtis syndrome.

blood cell count $\geq 10,000/\mu$ L). The significant predictive variables that favored acute appendicitis were a length of pain onset less than 2 days, no fever, no history of abortion, the absence of a coitus history within 4 weeks, no vaginal secretions, not taking painkiller for dysmenorrhea, localized right low quadrant tenderness, the presence of GI symptoms, migration of pain, and leukocytosis (Table 3).

3. Clinical risk score for PID and acute appendicitis

Each of these significant predictive variables was assigned a range of scores of 1 or 2. These weights were determined using the distribution of the β -coefficients from the multivariable logistic regression analyses. The β -coefficients for the PID model ranged from 0.909 to 2.255, with 1.632 being the midpoint, and the β -coefficients for the acute appendicitis model ranged from 0.799 to 2.117, with 1.498 being the midpoint. We assigned a weight of 1 to the predictors with a $\beta < 1.632$ and a weight of 2 to the predictors with a $\beta \ge 1.632$ for the PID score. We also assigned a weight of 1 to predictors with a $\beta < 1.498$ and a weight of 2 to predictors with a $\beta \ge 1.498$ for the acute appendicitis score. The total scores of PID and acute appendicitis were 12 points and 14 points, respectively. The ROC areas for the each scores were 0.896(95% CI: 0.859-0.933) for PID and 0.910(95% CI: 0.875-0.944) for acute appendicitis.

4. Validity and performance of the PID and acute appendicitis risk scores

Among the PID and acute appendicitis scored, lower and higher risk score cutoff points were assigned by using the sensitivity and specificity that were over 95%, respectively. The lower and higher cutoff points were 3 and 8 for PID, and 6 and 10 for acute appendicitis. We obtained sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio for the PID and acute appendicitis according to each cutoff point, respectively (Table 4). Finally, the proportions of the probability of PID and acute appendicitis were divided by into the low, intermediate and high risk groups by using these cutoff points, respectively. The proportions of risk for PID and acute appendicitis were 3.2% and 1.7% for the low risk

Table 2. The clinical characteristics of PID and acute appendicitis

| Mein ±SD ⁺ 28.9 ± 7.7 28.9 ± 8.5 0.99 Married 57 (36.8) 50 (46.7) 0.545 Pain onset (days) 4.1 ± 4.5 1.4 ± 1.8 <0.000 PD* hisory 105 (67.7) 35 (28.2) <0.001 PD* hisory 43 (27.7) 15 (12.1) 0.001 Abortion 72 (46.5) 28 (22.6) <0.000 Other noninfectious gynecologic diseases 50 (32.3) 21 (16.9) 0.004 Other noninfectious gynecologic diseases 16 (10.3) 8 (6.5) 0.253 Menstruation 1ast period (days ago) Tregular 57 (36.8) 58 (46.8) 0.092 Yes 25 (35.5) 47 (37.9) 0.667 Menorthagia 52 (33.5) 45 (36.3) 0.633 Yes 119 (76.8) 69 (55.6) <0.000 Oysmenorthea (≥ one times/years) 111 (72.1) 81 (65.3) 0.227 Yes 111 (72.1) 81 (65.3) 0.227 14 (43.5) 0.059 Yes 111 (72.1) 81 (65.3) 0.227 14 (43.5) 0.059 Yes 111 (72.1) 81 (65 | Clinical characteristics Overall | PID* 155 (100) | Acute appendicitis 124 (100) | <i>p</i> -value |
|--|---|-------------------|---------------------------------|-----------------|
| Mein ±SD ⁺ 28.9 ± 7.7 28.9 ± 8.5 0.99 Married 57 (36.8) 50 (46.7) 0.545 Pain onset (days) 4.1 ± 4.5 1.4 ± 1.8 <0.000 | Age (years) | | | |
| $\begin{array}{llllllllllllllllllllllllllllllllllll$ | | 28.9 ± 7.7 | 28.9 ± 8.5 | 0.997 |
| Pain onset (days) Mean ± SD ⁷ 1, 4 ± 1, 4, 1 ± 4, 5, 1, 4 ± 1, 8, <0,000 ≥2 105 (67,7) 35 (28,2) <0,001 Phistory Yes 43 (27,7) 15 (12,1) 0,001 Morition Yes 50 (32,3) 21 (16,9) 0,004 Attificial abortion Yes 50 (32,3) 21 (16,9) 0,004 Dher noninfectious gynecologic diseases Person 16 (10,3) 8 (6,5) 0,253 Menstruation Last period (days ago) Merrorrhagia 57 (36,8) 58 (46,8) 0,002 Merrorrhagia 55 (35,5) 47 (37,9) 0,667 Menorrhagia 55 (35,5) 47 (37,9) 0,667 Menorrhagia 55 (35,5) 45 (36,3) 0,633 Vaginal secretions Yes 50 (22,3) 45 (36,3) 0,633 Vaginal secretions Yes 111 (72,1) 81 (65,3) 0,227 Taking a painkiller for dysmenorrhea 111 (72,1) 81 (65,3) 0,227 Taking a painkiller for dysmenorrhea 72 (46,8) 44 (35,5) 0,009 Yes 0,207 (23,7) 45 (4,9) <0,000 Yes 0,207 (23,7) 45 (12,1) 0,019 Yes 0,207 (23,7) 45 (12,1) 0,010 Meraterine device Yes 57 (36,8) 80 (64,5) <0,000 Diffuse upper 0,664,5 <0,000 Diffuse upper 0,664,5 <0,000 Diffuse upper 0,664,5 <0,000 Diffuse upper 0,664,5 <0,000 Diffuse upper 0,67 (40,9) 15 (12,1) 0,012 Migration of pain Yes 0,73 (36,8) 40 (4,32) 0,000 Diffuse lower 67 (69,1) 30 (23,2) 0,000 Diffuse lower 70 (44,5) 15 (84,7) <0,000 Diffuse lower 70 (44,5) 15 (84,7) <0,000 Diffuse lower 71 (27,3) (20,000 Diffuse lower 71 (27,3) (20,000 Diffuse lower 71 (27,3) (20,000 Diffuse lower 72 (46,5) 9 (7,4) (4,5) (3,3) 0,001 Diffuse lower 71 (27,3) (20,000 Diffuse lower 71 (27,3) (20,000 Diffuse lower 72 (46,5) 9 (7,4) (4,5) (3,3) 0,001 Diffuse lower 72 (4,5) 9 (7,4) (4,5) (3,3) 0,001 Diffuse lower 72 (4,5) 9 (7,4) (4,5) (3, | Marital status | | | |
| $\begin{array}{llllllllllllllllllllllllllllllllllll$ | Married | 57 (36.8) | 50 (46.7) | 0.545 |
| | Pain onset (days) | | | |
| PID* history 43 (27.7) 15 (12.1) 0.001 Abortion 72 (46.5) 28 (22.6) <0.000 | | 4.1 ± 4.5 | 1.4 ± 1.8 | < 0.000 |
| Yes 43 (27.7) 15 (12.1) 0.001 Abortion Yes 72 (46.5) 28 (22.6) <0.000 Artificial abortion Yes 50 (32.3) 21 (16.9) 0.004 Dher noninfectious gynecologic diseases Yes 16 (10.3) 8 (6.5) 0.253 Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia Yes 53 (35.5) 47 (37.9) 0.667 Yes 54 (36.3) 0.663 Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Yes 72 (46.8) 44 (35.5) 0.663 Yes 72 (46.8) 44 (35.5) 0.000 Dysmenorrhea (≥ one times/years) Yes 72 (46.8) 44 (35.5) 0.055 Sexual contact Yes 72 (46.8) 44 (35.5) 0.055 Sexual contact Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes 73 degree centigrade) Yes 75 (36.8) 80 (64.5) <0.000 Diffuse lower 67 (36.8) 80 (64.5) <0.000 Diffuse lower 75 (36.8) 80 (64.5) <0.000 Pifuse lower 75 (36.8) 80 (64.5) <0.000 Pifuse lower 80 Yes 74 14 (11.3) 0.001 Zevation of the WBC ⁺ count (>10,000/L) Mean ±SD ⁺ 10597±4011 1364±4729 0.011 Yes 10597±4011 1364±4729 0.017 Yes 10597±401 1 | ≥ 2 | 105 (67.7) | 35 (28.2) | < 0.001 |
| Yes 43 (27.7) 15 (12.1) 0.001 Abortion Yes 72 (46.5) 28 (22.6) <0.000 Artificial abortion Yes 50 (32.3) 21 (16.9) 0.004 Dher noninfectious gynecologic diseases Yes 16 (10.3) 8 (6.5) 0.253 Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia Yes 53 (35.5) 47 (37.9) 0.667 Yes 54 (36.3) 0.663 Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Metrorrhagia Yes 54 (46.8) 0.092 Yes 72 (46.8) 44 (35.5) 0.663 Yes 72 (46.8) 44 (35.5) 0.000 Dysmenorrhea (≥ one times/years) Yes 72 (46.8) 44 (35.5) 0.055 Sexual contact Yes 72 (46.8) 44 (35.5) 0.055 Sexual contact Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes 73 degree centigrade) Yes 75 (36.8) 80 (64.5) <0.000 Diffuse lower 67 (36.8) 80 (64.5) <0.000 Diffuse lower 75 (36.8) 80 (64.5) <0.000 Pifuse lower 75 (36.8) 80 (64.5) <0.000 Pifuse lower 80 Yes 74 14 (11.3) 0.001 Zevation of the WBC ⁺ count (>10,000/L) Mean ±SD ⁺ 10597±4011 1364±4729 0.011 Yes 10597±4011 1364±4729 0.017 Yes 10597±401 1 | PID* history | | | |
| Yes 72 (46.5) 28 (22.6) <0.000 Artificial abortion Yes 50 (32.3) 21 (16.9) 0.004 Dher noninfectious gynecologic diseases 16 (10.3) 8 (6.5) 0.253 Menstruation Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 55 (35.5) 47 (37.9) 0.667 Menorrhagia 52 (33.5) 45 (36.3) 0.633 Ves 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Yes 72 (46.8) 44 (35.5) 0.227 Taking a painkiller for dysmenorrhea 111 (72.1) 81 (65.3) 0.227 Taking a painkiller for dysmenorrhea 121 (78.1) 52 (41.9) <0.000 Yes 72 (46.8) 44 (35.5) 0.059 Secual contet 72 Yes 72 (46.8) 80 (64.5) 0.0199 Ves 73.8 degree centigrade) 72 (46.8) 80 (64.5) <0.000 Dysmenorthe device 121 (77.1) 5 (4.0) 0.199 Pever (≥ 37.8 degree centigrade) 72 (36.8) 80 (64.5) <0.000 Diffuse lower 67 (36.8) 80 (64.5) <0.000 Diffuse lower 67 (36.8) 80 (64.5) <0.000 Diffuse lower 67 (36.8) 105 (84.7) <0.000 Zes 72 (24.5) 114 (91.9) 0.031 Point (ausea/vomiting/diarrhea/postprandial pain) 89 (57.4) 45 (36.3) 0.001 Jeologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No No No No No No No No No No | | 43 (27.7) | 15 (12.1) | 0.001 |
| Artificial abortion Yes 50 (32.3) 21 (16.9) 0.004 Uher noninfectious gynecologic diseases Yes 16 (10.3) 8 (6.5) 0.253 Wenstruation Last period (days ago) Inregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 74 (37.9) 0.667 Yes 52 (33.5) 47 (37.9) 0.667 Yes 52 (33.5) 45 (36.3) 0.633 Vaginal scretions Yes 119 (76.8) 69 (55.6) <0.000 Dysmenorrhea (≥ one times/years) Yes 72 (46.8) 44 (35.5) 0.227 Taking a painkiller for dysmenorrhea Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes 72 (46.8) 44 (35.5) 0.000 Diffuse lowcer Contact 72 (46.8) 80 (64.5) <0.000 Diffuse lowcer Contact 72 (46.8) 80 (64.5) <0.000 Diffuse lower Contact 67 (66.1) 30 (23.2) 0.001 Localized right upper quadrant 69 (44.5) 15 (12.1) 0.002 Diffuse lower quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes (23.7) 45 (36.3) 4 (3.2) <0.000 Diffuse lower (23.7) (50.8) 80 (64.5) <0.000 Sexual contact Yes (24.9) 105 (84.7) <0.000 Rebound tenderness Yes (27.1) 44 (11.3) 0.001 Evation of the WBC ⁺ count (>10,000/µL) Mean±SD ⁺ 10597±4011 13364±4729 0.011 Yes (24.5) 91 (73.4) <0.000 Sexual of the CRP ^s level (>0.5 mg/dL) Mean±SD ⁺ 6.52±7,42 4.33±6.80 <0.000 Yes (10 (71.0) 71 (57.3) 0.017 Yes | Abortion | | | |
| Yes 50 (32.3) 21 (16.9) 0.004 Other noninfectious gynecologic diseases 7 Yes 16 (10.3) 8 (6.5) 0.253 Menstruation Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.022 Metrorrhagia 55 (35.5) 47 (37.9) 0.667 Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions 7 Yes 72 (46.8) 44 (35.5) 0.227 Faking a painkiller for dysmenorrhea 7 Yes 72 (46.8) 44 (35.5) 0.059 Secual contact 7 Yes 72 (46.8) 44 (35.5) 0.059 Yes 72 (46.8) 44 (35.5) 0.059 Faking a painkiller for dysmenorrhea 7 Yes 72 (46.8) 44 (35.5) 0.059 Factor (237.8 degree centigrade) 7 Yes 73 (36.8) 80 (64.5) <0.000 Juratuetrine device 7 Yes 77 (36.8) 80 (64.5) <0.000 Juratuetrine device 7 Yes 70 (36.8) 15 (12.1) 0.012 Juratuetrine device 7 Yes 70 (36.8) 10 (51.2) 0.000 Juratuetrine device 7 Yes 7 (36.8) 10 (64.7) <0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness 7 Yes 10 (99 (44.5) 105 (84.7) <0.000 Zeation of the MBC ¹ count (>10,001/µL) Mean ±SD ⁺ 10 (597 ±4011 11 (13.6) 44 (13.9) 0.001 Ievation of the WBC ¹ count (>10,000/µL) Mean ±SD ⁺ 10 (597 ±4011 11 (13.64 ±4729 0.011 Yes 10 (24.5) 91 (73.4) <0.000 Juratuetrine for 72 (46.5) 91 (73.4) <0.000 Juratuetrine | Yes | 72 (46.5) | 28 (22.6) | < 0.000 |
| Duer noninfectious gynecologic diseases Yes 16 (10.3) 8 (6.5) 0.253 Menstruation Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 55 (35.5) 47 (37.9) 0.667 Menorrhagia 52 (33.5) 45 (36.3) 0.633 Yes 52 (35.5) 47 (37.9) 0.667 Yes 52 (36.8) 45 (36.3) 0.633 Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes 12 (7.7) 5 (4.0) 0.199 Fever (≥ 37.8 degree centigrade) Yes 57 (36.8) 80 (64.5) <0.001 Irrauterine device 27.8 degree centigrade) Yes 57 (36.8) 80 (64.5) <0.001 Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Localized right upper quadrant 69 (44.5) 15 (12.1) <0.012 Jiffuse upper 67 (69.1) 30 (23.2) 0.001 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness 60 G1' symptoms (nausea/vomiting/diarrhea/postprandial pain) No No No No No No No No No No | Artificial abortion | | | |
| Yes 16 (10.3) 8 (6.5) 0.253 Menstruation Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia Yes 55 (35.5) 47 (37.9) 0.667 Menorrhagia 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Yes 72 (46.8) 44 (35.5) 0.227 Taking a painkiller for dysmenorrhea Yes 72 (46.8) 44 (35.5) 0.027 Yes 72 (46.8) 44 (35.5) 0.027 Yes 72 (46.8) 44 (35.5) 0.029 Prever (≥ 37.8 degree centigrade) Yes 12 (7.7) 5 (4.0) 0.199 Pever (≥ 37.8 degree centigrade) Yes 57 (36.8) 80 (64.5) <0.000 Diffuse upper 69 (44.5) 15 (12.1) 0.012 Migration of pain Yes 69 (44.5) 15 (12.1) 0.000 Diffuse upper 69 (44.5) 105 (84.7) <0.000 Diffuse lower (37.68, 4 (3.2) <0.000 Diffuse lower (44.5) 105 (84.7) <0.000 Diffuse lower (1000/µL) No (2000 Eventions (1000/µL) No (2000 Evention (1000/µL) Mean ±SD ¹ (107,10) 71 (57.3) 0.017 Puria (white blood cell count ≥5/HPF**) Yes | Yes | 50 (32.3) | 21 (16.9) | 0.004 |
| Menstruation Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 55 (35.5) 47 (37.9) 0.667 Menorrhagia 52 (33.5) 45 (36.3) 0.633 Yes 52 (33.5) 45 (36.3) 0.633 Yes 119 (76.8) 69 (55.6) <0.002 | Other noninfectious gynecologic diseases | | | |
| Last period (days ago) Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 55 (35.5) 47 (37.9) 0.667 Yes 55 (35.5) 47 (37.9) 0.667 Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Y Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions Y Yes 5111 (72.1) 81 (65.3) 0.227 Faking a painkiller for dysmenorrhea Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes 12 (7.7) 5 (4.0) 0.199 Pever (\geq 37.8 degree centigrade) Yes 37 (36.8) 80 (64.5) <0.000 Visuation of pain 72 (36.8) 80 (64.5) <0.000 Juignation of pain 73 (36.8) 80 (64.5) <0.000 Diffuse upper 69 (44.5) 15 (12.1) 0.012 Ves 0.021 (57.8) 49 (30.22) 0.000 Diffuse upper 69 (44.5) 15 (12.1) 0.0012 Localized right upper quadrant 57 (36.8) 40 (3.2) 0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Diffuse lower 67 (69.1) 30 (23.2) 0.000 Diffuse lower 169 (44.5) 105 (84.7) <0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Zebound tenderness 74 Yes 63 (40.6) 70 (56.5) 0.009 Yes 72 (45.5) 91 (73.4) 0.001 No 19 (45.5) 12.1) 12 (13.0 0.001 No 19 (45.5) 12 (12.1) 12 (12.1) 0.001 No 19 (20.22) 0.001 No 19 (45.5) 105 (84.7) 0.000 ZVAT ⁴ Yes 72 (45.5) 91 (73.4) 0.001 Evation of the WBC ⁺ count (>10,000/µL) Mean ±SD ⁺ 10597±4011 13364±4729 0.011 Yes 72 (46.5) 91 (73.4) 0.000 Elevation of the CRP ⁴ level (>0.5 mg/dL) Mean ±SD ⁺ 0.057±4011 13364±4729 0.011 Yes 10 (71.0) 71 (57.3) 0.017 Yuri (white blood cell count ≥5/HPF*) Yes 10 (20.000 ≥5/HPF*) | Yes | 16 (10.3) | 8 (6.5) | 0.253 |
| Irregular 57 (36.8) 58 (46.8) 0.092 Metrorrhagia 7 55 (35.5) 47 (37.9) 0.667 Menorrhagia 52 (33.5) 45 (36.3) 0.633 Ves 119 (76.8) 69 (55.6) <0.000 | Menstruation | | | |
| $\begin{array}{l c c c c c c c c c c c c c c c c c c c$ | Last period (days ago) | | | |
| Yes 55 (35.5) 47 (37.9) 0.667 Menorrhagia Yes 52 (33.5) 45 (36.3) 0.633 Yes 119 (76.8) 69 (55.6) <0.000 | Irregular | 57 (36.8) | 58 (46.8) | 0.092 |
| Menorrhagia 52 (33.5) 45 (36.3) 0.633 Yes 52 (33.5) 45 (36.3) 0.633 Yes 119 (76.8) 69 (55.6) <0.000 | Metrorrhagia | | | |
| Yes 52 (33.5) 45 (36.3) 0.633 Vaginal secretions 119 (76.8) 69 (55.6) <0.000 | Yes | 55 (35.5) | 47 (37.9) | 0.667 |
| Vaginal secretions 119 (76.8) 69 (55.6) <0.000 | Menorrhagia | | | |
| Ves 119 (76.8) 69 (55.6) <0.000 | Yes | 52 (33.5) | 45 (36.3) | 0.633 |
| Dysmenorrhea (≥ one times/years) Yes 1111 (72.1) 81 (65.3) 0.227 Taking a painkiller for dysmenorrhea Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact Yes within one month Intrauterine device Yes 2 (41.9) <0.000 Intrauterine device Yes 37 (23.9) 15 (12.1) 0.012 Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 Location of tenderness Diffuse upper 69 (44.5) 15 (12.1) <0.000 Locatized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Diffuse lower 67 (69.1) 30 (23.2) 0.001 Diffuse lower 169 (44.5) 105 (84.7) <0.000 Rebound tenderness Pres 63 (40.6) 70 (56.5) 0.009 Gl [†] symptoms (nausea/vomiting/diarrhea/postprandial pain) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] 10597±4011 13364±4729 0.011 Ves 72 (46.5) 91 (73.4) <0.000 Elevation of the CRP [¶] level (>0.5 mg/dL) Mean ± SD [↑] 6.52±7.42 4.33±6.80 <0.000 Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count ≥ 5/HPF**) Yes | Vaginal secretions | | | |
| Yes 111 (72.1) 81 (65.3) 0.227 Taking a painkiller for dysmenorrhea Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact 121 (78.1) 52 (41.9) <0.000 | Yes | 119 (76.8) | 69 (55.6) | < 0.000 |
| Faking a painkiller for dysmenorrhea 72 (46.8) 44 (35.5) 0.055 Yes 72 (46.8) 44 (35.5) 0.055 Sexual contact Yes 121 (78.1) 52 (41.9) <0.000 | Dysmenorrhea (\geq one times/years) | | | |
| Yes 72 (46.8) 44 (35.5) 0.059 Sexual contact 121 (78.1) 52 (41.9) <0.000 | Yes | 111 (72.1) | 81 (65.3) | 0.227 |
| Sexual contact Yes within one month 121 (78.1) 52 (41.9) <0.000 Intrauterine device Yes 12 (7.7) 5 (4.0) 0.199 Fever (≥ 37.8 degree centigrade) Yes 37 (23.9) 15 (12.1) 0.012 Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 Joiffuse upper Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Diffuse lower 69 (44.5) 15 (12.1) 0 (0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 Starbard Starbard S | Faking a painkiller for dysmenorrhea | | | |
| Yes within one month 121 (78.1) 52 (41.9) <0.000 | Yes | 72 (46.8) | 44 (35.5) | 0.059 |
| Intrauterine device Yes 12 (7.7) 5 (4.0) 0.199 Fever (≥ 37.8 degree centigrade) Yes 37 (23.9) 15 (12.1) 0.012 Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 Locatized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Diffuse upper 69 (44.5) 15 (12.1) <0.000 Locatized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Diffuse lower 67 (69.1) 30 (23.2) 0.001 Locatized right lower quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI ⁺ symptoms (nausea/vomiting/diarrhea/postprandial pain) No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] Yes 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC ⁺ count (>10,000/µL) Mean ± SD ⁺ 10597 ±4011 13364 ±4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 Elevation of the CRP [¶] level (>0.5 mg/dL) Mean ± SD ⁺ 6.52 ± 7.42 4.33 ± 6.80 <0.000 Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count ≥5/HPF**) Yes | Sexual contact | | | |
| Yes 12 (7.7) 5 (4.0) 0.199 Fever (≥ 37.8 degree centigrade) 37 (23.9) 15 (12.1) 0.012 Wigration of pain 37 (23.9) 15 (12.1) 0.012 Migration of pain 57 (36.8) 80 (64.5) <0.000 | Yes within one month | 121 (78.1) | 52 (41.9) | < 0.000 |
| Fever (≥ 37.8 degree centigrade) Yes 37 (23.9) 15 (12.1) 0.012 Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 Location of tenderness Diffuse upper 69 (44.5) 15 (12.1) <0.000 Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Localized right upper quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI [†] symptoms (nausea/vomiting/diarrhea/postprandial pain) No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] Yes 10597 ±4011 13364 ±4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 Elevation of the WBC [†] count (>10,000/µL) Mean ± SD [†] 6.52 ±7.42 4.33 ±6.80 <0.000 Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count ≥5/HPF**) Yes | Intrauterine device | | | |
| Yes 37 (23.9) 15 (12.1) 0.012 Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 Location of tenderness Diffuse upper 69 (44.5) 15 (12.1) <0.000 Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Localized right lower quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI [↑] symptoms (nausea/vomiting/diarrhea/postprandial pain) No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] Yes 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC ⁺ count (>10,000/ μ L) Mean \pm SD [↑] 10597 \pm 4011 13364 \pm 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 Elevation of the CRP [§] level (>0.5 mg/dL) Mean \pm SD [↑] 6.52 \pm 7.42 4.33 \pm 6.80 <0.000 Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count \geq 5/HPF**) Yes | Yes | 12 (7.7) | 5 (4.0) | 0.199 |
| Migration of pain Yes 57 (36.8) 80 (64.5) <0.000 | Fever (\geq 37.8 degree centigrade) | | | |
| Yes57 (36.8)80 (64.5)<0.000Location of tendernessDiffuse upper69 (44.5)15 (12.1)<0.000 | Yes | 37 (23.9) | 15 (12.1) | 0.012 |
| Location of tenderness Diffuse upper 69 (44.5) 15 (12.1) <0.000 Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 Diffuse lower 67 (69.1) 30 (23.2) 0.001 Localized right lower quadrant 69 (44.5) 105 (84.7) <0.000 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI ⁺ symptoms (nausea/vomiting/diarrhea/postprandial pain) No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] Yes 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC ⁺ count (>10,000/µL) Mean \pm SD [†] 10597 \pm 4011 13364 \pm 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 Elevation of the CRP [§] level (>0.5 mg/dL) Mean \pm SD [†] 6.52 \pm 7.42 4.33 \pm 6.80 <0.000 Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count ≥5/HPF**) Yes | Migration of pain | | | |
| Diffuse upper 69 (44.5) 15 (12.1) <0.000 | | 57 (36.8) | 80 (64.5) | < 0.000 |
| Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 | Location of tenderness | | | |
| Localized right upper quadrant 57 (36.8) 4 (3.2) <0.000 | Diffuse upper | 69 (44.5) | 15 (12.1) | < 0.000 |
| Diffuse lower 1 30 (23.2) 0.001 Localized right lower quadrant 67 (69.1) 30 (23.2) 0.001 Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI [†] symptoms (nausea/vomiting/diarrhea/postprandial pain) No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) No 129 (83.2) 114 (91.9) 0.031 CVAT [§] Yes 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC [†] count (>10,000/ μ L) Mean \pm SD [†] 10597 \pm 4011 13364 \pm 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 Elevation of the CRP [§] level (>0.5 mg/dL) Mean \pm SD [†] 6.52 \pm 7.42 4.33 \pm 6.80 <0.000 Yes 100 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count ≥ 5/HPF**) Yes | Localized right upper quadrant | 57 (36.8) | 4 (3.2) | < 0.000 |
| Rebound tenderness Yes 63 (40.6) 70 (56.5) 0.009 GI ⁺ symptoms (nausea/vomiting/diarrhea/postprandial pain) 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) 129 (83.2) 114 (91.9) 0.031 CVAT [§] 129 (83.2) 114 (11.3) 0.001 Elevation of the WBC ⁺ count (>10,000/ μ L) 10597 ± 4011 13364 ± 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | | | | 0.001 |
| Yes $63 (40.6)$ $70 (56.5)$ 0.009 GI ⁺ symptoms (nausea/vomiting/diarrhea/postprandial pain) $89 (57.4)$ $45 (36.3)$ 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) $89 (57.4)$ $45 (36.3)$ 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) $129 (83.2)$ $114 (91.9)$ 0.031 CVAT [§] $42 (27.1)$ $14 (11.3)$ 0.001 Elevation of the WBC ⁺ count (>10,000/µL) 10597 ± 4011 13364 ± 4729 0.011 Yes $72 (46.5)$ $91 (73.4)$ <0.000 Elevation of the CRP ¹ level (>0.5 mg/dL) 6.52 ± 7.42 4.33 ± 6.80 <0.000 Yes $110 (71.0)$ $71 (57.3)$ 0.017 Pyuria (white blood cell count $\geq 5/HPF^{**}$) Yes $100 (71.0)$ $71 (57.3)$ 0.017 | Localized right lower quadrant | 69 (44.5) | 105 (84.7) | < 0.000 |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Rebound tenderness | | | |
| No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) 129 (83.2) 114 (91.9) 0.031 CVAT [§] 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC count (>10,000/µL) 10597 ± 4011 13364 ± 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | Yes | 63 (40.6) | 70 (56.5) | 0.009 |
| No 89 (57.4) 45 (36.3) 0.001 Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) 129 (83.2) 114 (91.9) 0.031 CVAT [§] 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC count (>10,000/ μ L) 10597 ± 4011 13364 ± 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | GI [†] symptoms (nausea/vomiting/diarrhea/postprandial pain) | | | |
| Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy) 129 (83.2) 114 (91.9) 0.031 CVAT [§] 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC count (>10,000/ μ L) 10597 ±4011 13364 ±4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | | 89 (57.4) | 45 (36.3) | 0.001 |
| No $129 (83.2)$ $114 (91.9)$ 0.031 CVAT [§] $42 (27.1)$ $14 (11.3)$ 0.001 Elevation of the WBC ⁺ count (>10,000/µL) 10597 ± 4011 13364 ± 4729 0.011 Mean \pm SD ⁺ 10597 ± 4011 13364 ± 4729 0.011 Yes $72 (46.5)$ $91 (73.4)$ <0.000 Elevation of the CRP ¹ level (>0.5 mg/dL) 6.52 ± 7.42 4.33 ± 6.80 <0.000 Mean \pm SD ⁺ 6.52 ± 7.42 4.33 ± 6.80 <0.000 Yes $110 (71.0)$ $71 (57.3)$ 0.017 Pyuria (white blood cell count $\geq 5/HPF^{**}$)Yes Yes Yes | Urologic symptoms (dysuria/hematuria/frequency/residual urine/cloudy | ·) | | |
| $VAT^{\$}$ 42 (27.1) 14 (11.3) 0.001 Elevation of the WBC ⁺ count (>10,000/µL) 10597 ± 4011 13364 ± 4729 0.011 Mean ± SD ⁺ 10597 ± 4011 13364 ± 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | | | 114 (91.9) | 0.031 |
| Yes $42 (27.1)$ $14 (11.3)$ 0.001 Elevation of the WBC ^{II} count (>10,000/µL) 10597 ± 4011 13364 ± 4729 0.011 Mean \pm SD ⁺ 10597 ± 4011 13364 ± 4729 0.011 Yes $72 (46.5)$ $91 (73.4)$ <0.000 Elevation of the CRP ⁴ level (>0.5 mg/dL) 6.52 ± 7.42 4.33 ± 6.80 <0.000 Yes $110 (71.0)$ $71 (57.3)$ 0.017 Pyuria (white blood cell count $\geq 5/HPF^{**}$)Yes Yes Yes | CVAT [§] | ~ / | | |
| Elevation of the WBC ⁺⁺ count (>10,000/ μ L) 10597 ± 4011 13364 ± 4729 0.011 Yes 72 (46.5) 91 (73.4) <0.000 | | 42 (27.1) | 14 (11.3) | 0.001 |
| Mean \pm SD ⁺ 10597 \pm 401113364 \pm 47290.011Yes72 (46.5)91 (73.4)<0.000 | | () | (| |
| Yes 72 (46.5) 91 (73.4) <0.000 | | 10597 ± 4011 | 13364±4729 | 0.011 |
| Elevation of the CRP [¶] level (>0.5 mg/dL) 6.52 ± 7.42 4.33 ± 6.80 <0.000 | | | | |
| Mean \pm SD ⁺ 6.52 \pm 7.42 4.33 \pm 6.80 <0.000 | | .= (.0.5) | / (///// | .0.000 |
| Yes 110 (71.0) 71 (57.3) 0.017 Pyuria (white blood cell count \geq 5/HPF**) Yes 110 (71.0) 110 (71.0) 11 (57.3) | | 6.52 ± 7.42 | 4.33 ± 6.80 | <0.000 |
| Pyuria (white blood cell count \geq 5/HPF**) Yes | | | | |
| Yes | | | (01.0) | 0.017 |
| | | | | |
| | No | 99 (65.1) | 97 (78.9) | 0.013 |

* PID: pelvic inflammatory disease, [†] SD: standard deviation, [†] GI: gastrointestinal, [§] CVAT: costovertebral angle tenderness, [∥] WBC: white blood cell, ¹ CRP: c-reactive protein, ** HPF: high power field.

group, 49.5% and 32.3% for the intermediate risk group and 96.9% and 93% for the high risk group, respectively (Table 5).

Discussion

PID is a clinical syndrome that has been defined by the Centers for Disease Control and Prevention (CDC) as a spectrum of upper genital tract infections that includes any combination of endometritis, salpingitis, pyosalpinx, TOA and pelvic peritonitis. In the 2006 center for disease control (CDC) guideline, there were minimum criteria and additional supportive criteria for making the diagnosis of PID⁸⁾. The minimum criteria included cervical motion tenderness (CMT), uterine tenderness and adnexal tenderness. The supportive criteria included an increase of the body temperature (BT), leukorrhea, vaginal secretions, an elevated erythrocyte sedimentation rate or CRP level, and cervical infection with Neisseria gon-

 Table 3. The statistically significant predictive variables of PID and acute appendicitis by multivariable logistic regression analysis

| | | | PID* | | | | appendicitis | |
|------------------------------------|------------------------|-------|------------------------|-----------------|------------------------|-------|--------------|-----------------|
| Predictor variables | ROC ⁺ 0.896 | | ROC ⁺ 0.910 | | | | | |
| | \mathbf{B}^{\dagger} | OR§ | 95% CI | <i>p</i> -value | \mathbf{B}^{\dagger} | OR § | 95% CI | <i>p</i> -value |
| Pain onset | | | | | | | | |
| <2 dyas | | | | | | | | |
| ≥ 2 days | 2.255 | 9.538 | 4.417-20.596 | < 0.001 | 2.117 | 8.303 | 3.734-18.461 | < 0.001 |
| Fever (>37.8° C) | | | | | | | | |
| Yes | 1.442 | 4.228 | | 0.005 | | | | |
| No | | | | | 1.499 | 4.476 | 1.610-12.441 | 0.004 |
| Abortion | | | | | | | | |
| Yes | 1.142 | 3.132 | 1.440-6.816 | 0.004 | | | | |
| No | | | | | 1.244 | 3.468 | 1.582-7.601 | 0.002 |
| Vaginal secretions | | | | | | | | |
| Yes | 1.087 | 2.965 | 1.424-6.173 | 0.004 | | | | |
| No | | | | | 1.098 | 2.997 | 1.402-6.407 | 0.005 |
| Taking a painkiller for dysmenorrh | ea | | | | | | | |
| Yes | | 2.542 | 1.219-5.300 | 0.013 | | | | |
| No | | | | | 0.962 | 2.616 | 1.238-5.526 | 0.012 |
| Sexual contact | | | | | | | | |
| Yes within one month | 1.546 | 4.693 | 2.257-9.757 | < 0.001 | | | | |
| No within one month | | | | | 1.816 | 6.144 | 2.812-13.426 | < 0.001 |
| Location of tenderness | | | | | | | | |
| Diffuse lower or bilateral | 0.909 | 2.482 | 1.186-5.195 | 0.016 | | | | |
| Localized right lower quadrant | | | | | 1.743 | 5.713 | 2.566-12.721 | < 0.001 |
| Migration of pain | | | | | | | | |
| Yes | | | | | 1.050 | 2.858 | 1.357-6.019 | 0.006 |
| No | 1.342 | 3.827 | 1.878-7.798 | < 0.001 | | | | |
| Gastro-intestinal symptoms | | | | | | | | |
| Yes | | | | | 0.779 | 2.178 | 1.054-4.503 | 0.036 |
| No | 0.909 | 2.481 | 1.230-5.001 | 0.011 | | | | |
| Elevation of the WBC count | | | | | | | | |
| (>10,000/µL) | | | | | | | | |
| Yes | | | | | 0.854 | 2.348 | 1.086-5.077 | 0.03 |
| No | 1.010 | 2.745 | 1.299-5.799 | 0.008 | | | | |

* PID: pelvic inflammatory disease

⁺ ROC: receiver operating characteristics

[†] B: beta-coefficient

§ OR: odds ratio

^{II} CI: confidence interval.

orrhea or Chlamydia trachomatis. Acute PID infections are associated not only with psychological, economic and public health burdens, but also with long-term sequelae, including infertility, ectopic pregnancy, recurrent PID, chronic pelvic pain and cancer⁹⁻¹³⁾. Making the differential diagnosis between PID and acute appendicitis using only a physical examination and laboratory findings has been of the oldest unsolved problems in EDs. There have been many attempt to screen for gynecological infection, such as sexually transmitted diseases and PID, and to create a feasible technique for rapidly detecting the chlamydial and gonococcal infections in EDs¹⁴⁻²⁰⁾. There have been some studies about the underrecognition, misdiagnosis and under-treatment of chlamydial and gonococcal infection in EDs^{1,2,4)}. The clinical diagnosis of PID is imprecise and difficult because of the wide variations of signs and symptoms; many women with PID exhibit subtle, vague or mild symptoms²¹⁻²³⁾. PID might progress to peritonitis in the pelvic cavity or the intra-abdominal space due to ascending infection, which is mainly Chlamydia trachomatis and some other organisms. FHCS is complication of uncured PID and it might develop by ascending infection of the causative organisms from the pelvic cavity to the capsule of the liver^{24,25)}. Therefore, FHCS should be treated with the same regimen as that of PID. We also considered that FHCS was a PID-related disease and it was counted in the criteria of PID. The characteristics of FHCS patient are pleuritic RUQ pain, migration of pain from the low abdomen to the upper abdomen and sometimes to the right CVAT²⁴⁾.

The length of stay in the ED may be increased by conducting further studies and examination for making the differential diagnosis. We might overcome this weak point for childbearing women with abdominal pain by conducting screening programs or creating a scoring system. We developed some different scoring systems for predicting PID and acute appendicitis in childbearing women with abdominal pain from previous studies¹⁷. We assigned a range of scores of 1 or 2 points to each of the significant predictive variables by using the distribution of the β -coefficients from the multivariable logistic regression analyses. We categorized the risk groups of the PID and acute appendicitis scores into the low, inter-

| Diagnosis | Cutoff point | Sensitivity | Specificity | PPV* | \mathbf{NPV}^{\dagger} | PLR^{\dagger} | NLR [§] |
|--------------------------|--------------|-------------|-------------|-------------|--------------------------|-----------------|------------------|
| PID | ≥ 3 | 99.4 | 24.2 | 61.9 | 96.8 | 1.31 | 0.03 |
| | | (95.9-100) | (17.2-32.9) | (55.5-68.0) | (81.5-99.8) | (1.19-1.45) | (0.00-0.20) |
| | ≥ 8 | 40.9 | 98.4 | 96.9 | 57.3 | 25.40 | 0.60 |
| | | (33.2-49.1) | (93.7-99.7) | (88.4-99.5) | (50.3-64.0) | (6.33-101.60) | (0.53-0.69) |
| Acute appendicit | is ≥ 6 | 99.2 | 37.7 | 56.2 | 98.3 | 1.59 | 0.02 |
| | | (94.9-100) | (30.1-45.9) | (49.3-62.8) | (89.7-99.9) | (1.41-1.80) | (0.00-0.15) |
| | ≥ 10 | 64.5 | 96.1 | 93.0 | 77.1 | 16.56 | 0.37 |
| | | (55.4-72.8) | (91.3-98.4) | (84.9-97.1) | (70.4-82.7) | (7.48-36.68) | (0.29-0.47) |

Table 4. Validity of prediction method for the PID and acute appendicitis according to each scores

95% Confidence interval in parentheses.

* PPV: positive predictive value

[†] NPV: negative predictive value

[†] PLR: positive likelihood ratio

[§] NLR: negative likelihood ratio

^{II} PID: pelvic inflammatory disease.

| Table 5. Risk status and | proportions accordin | g to the risk score for PID | and acute appendicitis |
|---------------------------------|----------------------|-----------------------------|------------------------|
| | | | |

| | P | ID* | Acute appendicitis | | |
|--------------|-----------------------|----------------|-----------------------|----------------|--|
| Risk Status | Interval of the score | Proportion (%) | Interval of the score | Proportion (%) | |
| Low | 0~2 | 1/31 (3.2) | 0~5 | 1/59 (1.7) | |
| Intermediate | 3~7 | 90/182 (49.5) | 6~9 | 43/133 (32.3) | |
| High | $\geq \! 8$ | 63/65 (96.9) | ≥ 10 | 80/86 (93.0) | |

* PID: pelvic inflammatory disease.

mediate and high risk groups. So for the high PID risk patient, the emergency physician should first call a gynecologist to conduct a gynecologic examination with trans-vaginal ultrasonography. In contrast, for the acute appendicitis risk patients, the emergency physician should first confirm acute appendicitis by using abdominal ultrasonography or CT and then a surgeon should be consulted according to the results of these studies.

Further study will be needed for prospectively validating our scoring system in our hospital and other hospital.

Our study had the following limitations. First, our study was a single-center study. Second, some other predictor variables such as the socioeconomic status, a medication history of oral contraceptives, condom use, smoking and the number of sexual partners were not counted in our study.

Conclusion

We developed scoring systems for childbearing-aged women who present with abdominal pain to screen for PID and acute appendicitis, among other diseases, by using eleven important factors. Further prospective study that will use these scoring systems is needed.

REFERENCES

- Bachmann LH, Pigott D, Desmond R, Jones M, Lumpkins J, Gala P, et al. Prevalence and factors associated with gonorrhea and chlamydial infection in at-risk females presenting to an urban ED. Sex Transm Dis 2003;30:335-9.
- 2. Yealy DM, Greene TJ, Hobbs GD. Underrecognition of cervical neisseria gonorrheae and chlamydial trachomatis infections in the ED. Acad Emerg Med 1997;10:962-7.
- Mehta SD, Rothman RE, Kelen GD, Quinn TC, Zenilman JM. Unsuspected gonorrhea and Chlamydia in patients of an urban adult emergency department: a critical population for STD control intervention. Sex Transm Dis 2001;28:33-9.
- Doxanakis A, Hayes RD, Chen MY, Gurrin LC, Hocking J, Bradshaw CS, et al. Missing pelvic inflammatory disease? Substantial differences in the rate at which doctors diagnose PID. Sex Transm Dis 2008;84:518-23.
- 5. Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al. Radiation dose associated with common computed tomography examinations and the associated

lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078-86.

- Brenner DJ, Hall EJ. Computed Tomography-An increasing source of radiation exposure. N Engl J Med 2007;357: 2277-84.
- Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hanson R, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009;251:175-84.
- Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55:1-94.
- Westrom L, Joeseof R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort of 1,844 women with laparoscopically verified diseases and 657 control women with normal laparoscopic results. Sex Transm Dis 1992;19:185-92.
- Simms I, Stephenson JM. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know? Sex Transm Infect 2000;76:80-7.
- Brunham RC, Binns B, Guijon F, Danforth D, Kosseim ML, Rand F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1998;158:510-7.
- Anttila T, Saikku P, Koskela P, Bloiqu A, Dillner J, Ikä heimo I, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47-51.
- 13. Ness RB, Soper DE, Richter HE, Randall H, Peipert JF, Nelson DB, et al. Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis 2008;35:129-35.
- Al-Tayyib AA, Miller WC, Rogers SM, Leone PA, Law DC, Ford CA, et al. Evaluation of risk score algorithms for detection of chlamydial and gonococcal infections in an emergency department setting. Acad Emerg Med 2008; 15:126-35.
- Ness RB, Smith KJ, Chang CC, Schisterman EF, Bass DC. Prediction of Pelvic Inflammatory Disease Among Young, Single, Sexually Active Women. Sex Transm Dis 2006; 33:137-42.
- Morishita K, Gushimiyagi M, Hashiguchi M, Stein GH, Tokuda Y. Clinical prediction rule to distinguish pelvic inflammatory disease from acute appendicitis in women of childbearing age. Am J Emerg Med 2007;25:152-7.
- Berwald N, Cheng S, Augenbraun M, Abu-Lawi K, Lucchesi M, Zehtabchi S. Self-administered vaginal swabs are a feasible alternative to physician-assisted cervical swabs for sexually transmitted infection screening in the emergency department. Acad Emerg Med 2009;16:360-3.
- 18. Shapiro T, Dalton M, Hammock J, Lavery R, Matjucha J,

Salo DF. The prevalence of urinary tract infections and sexually transmitted disease in women with symptoms of a simple urinary tract infection stratified by low colony count criteria. Acad Emerg Med 2005;12:38-44.

- Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6.
- 20. Wachington AE, Aral SO, Wolner-Hanssen P, Grimes DA, Holmes KK. Assessing risk for pelvic inflammatory disease and its sequelae. JAMA 1991;266:2581-6.
- 21. Sweet RL, Shachter J, Robbie MO. Failure of beta-lactams antibiotics to eradicate Chlamydia trachomatis in the endometrium despite apparent clinical cure of acute salp-

ingitis. JAMA 1983;250:2641-5.

- 22. Henry-Suchet J, Loffredo V. Chlamydia and mycolasma genital infection in salpingitis and tubal sterility. Lancet 1980;1:539.
- 23. Wiessenfeld HC, Hiller SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002;100:456-63.
- 24. Peter NG, Clark LR, Jaeger JR. Fitz-Hugh-Curtis syndrome: a diagnosis to consider in women with right upper quadrant pain. Cleve Clin J Med 2004;71:233-9.
- 25. Nishie A, Yoshimiusu K, Irie H, Yoshitake T, Aibe H, Tajima T, et al. Fitz-Hugh-Curtis syndrome radiologic manifestation. J Comput Assist Tomogr 2003;27:786-91.